An unwelcome situation has developed in neurologof this editorial, beta interferon-1-b (Betaseron, Schering) will have been granted a product licence in ical out-patient practice recently, threatening to desthe UK. Consequently neurological units are bracing troy the good relationships usually enjoyed by themselves for what they fear will be a barrage of patients and their specialists. All neurologists accept patients with multiple sclerosis who will have that once they have made a diagnosis of an untreatincreased expectations of receiving the drug. able chronic disabling disease in a patient, they However, the granting of a licence will do nothing to should continue to see that patient on an occasional increase the information available to neurologists out-patient basis, recognizing their role as a specialist regarding the efficacy of the drug and the decision who can offer advice, explanation and support.
whether or not to prescribe will be yet more difficult. Neurological out-patient review may be the route of The task will be to balance the expectations of referral to physiotherapy departments, community patients with reality. At the time of writing, groups of nurse specialists, patient support groups and the neurologists in individual centres are trying to formusource of medication to treat some or all of the comlate their own policy for this difficult question, and it plications of the underlying condition. Inevitably the is possible that we shall see a situation with neurolopatient and the neurologist build up a relationship of gists in one major centre announcing that they simply trust, and can generally share discussions about probwill not prescribe because they are not convinced of lems and new ideas for treatment. In many ways the benefit, whereas another centre may offer a recompatient and the neurologist act together as a team mendation for treatment of all their local patients whose goal is the defeat, or at least the control, of meeting the indications for the drug stated in the the illness.
licence. Chaos will ensue. In a number of multiple sclerosis patients attending
The interferons are not really drugs at all, but natneurological out-patients during the past few months, urally occurring substances which were first recogthis bond between patient and neurologist has been nized in the 1950s as chemical messengers released broken. The destructive force resulting in this deteriby infected cells.1 A classification has evolved over oration in the neurologist-patient relationship is the the years, and presently this assigns interferons to arrival of beta interferon, an agent perceived either three groups, alpha, beta (sometimes grouped rightly or wrongly by patients as something which together as the 'type 1' interferons) and gamma will significantly improve their condition, and per-('type 2 interferon'). Alpha interferon has been shown haps even halt the disease in its tracks. The probto have a role in the treatment of some viruslem-as seen by the patient with multiple sclerosisassociated malignancies and now has an established is that their neurologist seems unable or unwilling to track record. Gamma interferon tends to augment prescribe the new drug for them. The converse is that immune function, and in the context of multiple the neurologist is-in general-yet to be convinced sclerosis, seems to have a disease-exacerbating effect. that the drug offers anything other than modest beneBeta interferon appears to counteract some of the fit to the patient, and moreover has an unproven actions of gamma interferon, and for this reason alone safety record, so enthusiasm to prescribe the drug is could offer benefit in multiple sclerosis. But if we lacking. To complicate matters, the cost of treatment assume that multiple sclerosis occurs in genetically of one individual with multiple sclerosis for one year susceptible individuals as a result of a misdirected is of the order of £10 000, and this price is known immune response to a component of myelin, then both by neurologist and patient. The patient infers there are other theoretical reasons why beta interfrom the doctor's reluctance to prescribe that treatferon may be beneficial by suppressing abnormal ment is being denied on grounds of cost, and the immune activity. Possible mechanisms of benefit result is often misery and acrimony unsettling a include suppression of abnormal T-lymphocyte activdoctor-patient relationship which may have flourity, down-regulation of the expression of proteins of ished over many years. the major histocompatibility complex or enhancement of T-suppressor-cell function.2 It seems probable that by the time of publication The precise mechanism of alleged benefit of beta between the amount of abnormality on a scan and the severity of multiple sclerosis in a given patient, interferon in multiple sclerosis is not known, but the theoretical arguments were strong enough to lead to there is as yet no good correlation between the two.7,8 A second major study of beta interferon in patients preliminary trials in the early 1980s. Most of the early trials were hindered by small numbers of patients and with multiple sclerosis is being much talked about. At the time of writing (October 1995), the results of this lack of blinding, making meaningful analysis difficult. Often only very small quantities of beta interferon study frustratingly have not been published in any peer-reviewed form, but oral presentations of the data were available for study. Nevertheless initial studies suggested that in those patients who had a relapsinghave been made at international conferences.9 This study used a marginally different form of interferon remitting pattern of illness, the frequency of relapses in the treated group was reduced. Further small stud-(Interferon-beta-1a, Biogen), and is important because the main outcome measure was disability, ies3 culminated in a major multicentre collaborative trial of beta interferon in patients with relapsingand the trial appeared to show a positive benefit. Again the study concentrated on patients with the remitting multiple sclerosis, and the results of this trial were published in April 1993.4 A total of 372 patients relapsing-remitting form of multiple sclerosis and in this case the patients received either high-dose beta were randomly assigned to receive high-dose beta interferon, low-dose, or placebo. The interferon was interferon or placebo as an intramuscular injection on a once-weekly basis. The main outcome measure given by subcutaneous injection on alternate days, and the patients were followed up for two years. The was the time taken to progress by one point on the 'expanded disability status scale' (EDSS) devised by number of relapses experienced by patients in the high-dose group was reduced by one third in comparDr John Kurtzke, which is widely used as a rating scale to describe the severity of multiple sclerosis in ison to the number of relapses experienced by patients in the other two groups. The trial has been an individual. They recruited 301 patients into this trial, and amongst those who completed the study, criticized for inadequate blinding, especially of the patients, many of whom experienced flu-like sympthere was a significant delay in the time taken to progress by one EDSS point in the group receiving toms on the active agent, so raising concern that the reporting of relapses was biased. Moreover, there active agent in comparison with the placebo group. Unfortunately, although the Kurtzke expanded disabwere a large number of patient drop-outs for assorted reasons, who were not included in the final analysis ility status scale enjoys widespread usage, almost all authorities in the field of multiple sclerosis research of the results. Subsequent observation of the patients who remained in the study for a total of five years has have reservations about it, questioning its validity and applicability in the context of clinical trials, and in shown that the effect of beta interferon on relapse rate is maintained5 but this result has also been quesparticular questioning whether a move between two points on the scale by one individual is a meaningful tioned, since the analysis was not made on an 'intention-to-treat' basis. assessment of accumulation of disability.10,11 Several other studies are currently underway both Whilst the outcome of this trial is of interest and encouraging, the positive result in terms of an effect in Europe and North America. Some of these are concentrating on patients with relapsing-remitting on relapse rate is not the question which neurologists and their patients most want answered. Their main multiple sclerosis, and others are looking at any effect on primary progressive and secondary progressive concern is whether or not the drug slows down the overall progression of the disease, in other words forms of the disease. The two major trials described above recruited only individuals with multiple sclerwhether it can slow down the accumulation of disability. This question was addressed by the study, but osis who were still able to walk unaided, so the study populations were not representative of the multiple the result was negative. Despite this disappointing finding, the authors of the study and the manufactursclerosis population as a whole, and current studies are looking for a benefit of beta interferon in more ing company involved have made much of a reduction in the abnormal area seen on cranial magnetic severely disabled individuals. The problem faced by neurologists and their resonance scans of the patients in the high-dose group.6 This was one of the secondary outcome patients with multiple sclerosis is that great weight has been placed on the results of the two major measures of the study, and clearly showed a positive benefit in the so-called 'lesion load'. In the placebo studies described above. Few would argue that the Interferon-beta-1b study4 has shown that the agent group after two years, the mean area of abnormality on the MRI scans had increased by 20%, but in the has a modest effect on the frequency-but not necessarily the severity-of relapses, but this is not the group treated with the high-dose active agent, the abnormal area had decreased by 0.1%. Exciting result that the multiple sclerosis population needs.
What is needed is a study which tells us whether or though this may be in theoretical terms, it is still not the result most needed by patients or their physicians, not beta interferon can usefully slow the progression of disability in multiple sclerosis patients. For the start since whilst there may be some emerging association of an answer to this we can look at the Biogen study, disease, are already demanding that they be prescribed the drug regardless of the view of the neurolobut this must be substantiated by further large-scale gist or the 'official indication'. If they have the 'wrong trials, and neurologists will want to see a result more sort' of multiple sclerosis, disability which is too meaningful than a slight slowing of the time it takes advanced, or simply a neurologist who is more scepfor ambulant patients to progress by one point on a tical about the data than others, then there will be yet scale of questionable usefulness. We really need to more cries of 'health care rationing' added to the know about differences in the speed of accumulation chorus of voices already raised in protest at perceived of major disability, probably over a trial period of 'meanness' on the part of neurologists. some years. This approach to the question has been
If beta interferon were as cheap as aspirin, and had rather crudely referred to as a 'count the wheelchairs' an established safety record, then neurologists would sort of trial, that is, take a large number of patients, almost certainly be willing to give it a try on the give beta interferon or placebo, and after a long trial strength of the data currently available. Conversely, if period use a very simple outcome measure, such as it were the subject of a series of rigorous independent how many patients need to use a wheelchair, to look clinical trials with unequivocal evidence of effective for any benefit. If we could somehow confine the slowing of disability accumulation, then neurologists study population to those individuals who might be would prescribe it, even at the current enormous cost. expected to show a rapid accumulation of disability, Unfortunately it is neither, hence the fuss. perhaps by scrutinizing rate of change on serial MRI C.J. Mumford scans in the pre-trial period, then the study could Department of Clinical Neurosciences feasibly be done in just a few years in a relatively
Western General Hospital small number of patients. The granting of a licence to Edinburgh beta interferon at this stage in the acquisition of data may now mean that the performance of such a trial becomes impossible, both in ethical terms and in the ability to find patients willing to enter a study with
